Pfizer Inc. (NYSE:PFE) Shares Purchased by MetLife Investment Management LLC

MetLife Investment Management LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 1.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,500,026 shares of the biopharmaceutical company's stock after purchasing an additional 26,451 shares during the quarter. MetLife Investment Management LLC's holdings in Pfizer were worth $39,796,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC acquired a new position in Pfizer during the 4th quarter valued at about $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer during the fourth quarter worth about $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer during the fourth quarter valued at about $28,000. Noble Wealth Management PBC purchased a new position in shares of Pfizer in the 4th quarter valued at approximately $31,000. Finally, Curio Wealth LLC purchased a new stake in Pfizer during the 4th quarter worth approximately $32,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

Shares of Pfizer stock traded down $0.07 during mid-day trading on Monday, reaching $22.07. 31,814,050 shares of the stock traded hands, compared to its average volume of 40,452,372. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The stock has a market capitalization of $125.17 billion, a PE ratio of 15.65, a PEG ratio of 0.64 and a beta of 0.67. The business has a 50-day moving average of $24.81 and a 200 day moving average of $26.11.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same period in the prior year, the business earned $0.10 earnings per share. The company's quarterly revenue was up 24.7% compared to the same quarter last year. On average, analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on PFE shares. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup reissued a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. UBS Group decreased their target price on Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a report on Tuesday, April 8th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of "Moderate Buy" and an average price target of $31.07.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.06% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.